MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Vedolizumab (anti-α4β7-integrin)

CAS No. : 943609-66-3

MCE 站：Vedolizumab (anti-α4β7-integrin)

产品活性：Vedolizumab (anti-α4β7-integrin) 是一种靶向 α4β7 整联蛋白 (integrin) 的人源化 IgG1 单克隆抗体，用于溃疡性结肠炎和克罗恩病的相关研究。

研究领域：Cytoskeleton

作用靶点：Integrin

In Vitro: Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, ａnd most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, ａnd to naive T-helper lymphocytes, naive ａnd memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, ａnd basophils at lower levels; vedolizumab binds to memory CD4+ T ａnd B lymphocytes with subnanomolar potency (EC₅₀=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC₅₀=0.02-0.06 g/mL) ａnd fibronectin (IC₅₀=0.02 g/mL), but not vascular cell adhesion molecule 1.

In Vivo: Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab ａnd 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively ａnd saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose ａnd when regular induction infusions are used (on day 1, 15, 29 ａnd 85), the serum half-life is between 15 ａnd 22 days across all groups.

相关产品：Cilengitide  |  CWHM-12  |  Cyclo(-RGDfK)  |  MK-0429  |  GLPG0187  |  E7820  |  iRGD peptide  |  ATN-161 trifluoroacetate salt  |  Lifitegrast  |  Cucurbitacin B  |  Arg-Gly-Asp-Ser  |  A-205804  |  ILK-IN-3  |  Eptifibatide  |  Pyrintegrin  |  αvβ1 integrin-IN-1 TFA  |  RGD Trifluoroacetate  |  Leukadherin-1  |  OSU-T315  |  Natalizumab  |  RGD peptide (GRGDNP) (TFA)  |  Vedolizumab  |  Firategrast  |  Tetrac  |  Carotegrast methyl  |  Tirofiban  |  BIO5192 hydrate  |  Zaurategrast

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。